The impaired response of NK cells from HIV-infected progressor patients to A-class CpG oligodeoxynucleotides is largely dependent of a decreased production of IL-12

Immunology Letters

Volumn 109, Issue 1, 2007, Pages 83-90

  Saez, Raquel ^a   Echaniz, Pilar ^a   Juan, Maria Dolores De ^a   Iribarren, Jose Antonio ^a   Cuadrado, Emilio ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

CpG DNA; HIV infection; Innate immunity; NK cells

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY;

ADULT; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES;

EID: 33847630800     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.01.006     Document Type: Article

References (49)

1. Levy J.A. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 22 (2001) 312-316
2. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., and Salazar-Mather T.P. Natural killer cells in anti viral defence: function and regulation by human cytokines. Annu Rev Immunol 17 (1999) 189-220
3. Fehniger T.A., Herbein G., Yu H., Para I., Bernstein Z.P., O' Brien W.A., et al. Natural killer cells from HIV-infected individuals are an important source of CC-chemokines and inhibit HIV-1 infection. J Immunol 161 (1998) 6433-6438
4. Brenner B.G., Grillis C., Gornitsky M., and Wainberg M.A. Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol 93 (1993) 142-148
5. Ironson G., Balbin E., Solomon G., Fahey J., Klimas N., Schneiderman N., et al. Relative preservation of natural killer cell activity and number in healthy AIDS patients with low CD4 cell counts. AIDS 15 (2001) 2065-2073
6. Villanueva J.L., Caballero J., del Nozal M., Sanchez B., Viciana P., Alarcon A., et al. Peripheral blood natural killer cell reconstitution after highly active antiretroviral therapy. AIDS 14 (2000) 473-474
7. Weber K., Meyer D., Gross V., Stoll M., Schmidt R.E., and Heiken H. Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology 202 (2000) 172-178
8. Scott-Algara D., Truong L.X., Versmisse P., David A., Luong T.T., Nguyen N.V., et al. Increased NK cell activity in HIV-1 exposed but uninfected Vietnamese intravascular drug users. J Immunol 171 (2003) 5663-5667
9. Frey M., Packienathan N.B., Fehniger T.A., Ross M.E., Wang W.C., Stewart C.C., et al. Differential expression and function of l-selectin on CD56 bright and CD56 dim natural killer cell subsets. J Immunol 161 (1998) 400-408
10. Jacobs R., Hintzen G., Kemper A., Beul K., Kempf S., Behrens G., et al. CD56 bright cells differ in their KIR repertoire and cytotoxic features from CD56 dim NK cells. Eur J Immunol 31 (2001) 3121-3126
11. Young -J., Kanzler H., Soumelis V., and Gilliet M. Dendritic cell lineage, plasticity and cross regulation. Nat Immunol 2 (2002) 585-589
12. Smed-Sorensen A., Lore K., Vasudevan J., Londer K., Andersson J., Mascola J.R., et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol 79 (2005) 8861-8869
13. Soumelis V., Scott I., Gehas F., et al. Depletion of circulating natural type interferon-producing cells in HIV-infected AIDS patients. Blood 98 (2001) 906-912
14. Donaghy H., Pozniazk A., Gazzard B., et al. Loss of blood CD11c+ myeloid and CD11c-plasmacytoid dendritic cells in patients with HIV infection correlates with HIV-1 RNA viral load. Blood 98 (2001) 2574-2576
15. Chechimi J., Campbell D.E., Azzoni L., et al. Persistent decrease in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 168 9 (2002) 4796-4801
16. Gerosa F., Aldani-Gerra C., Nisii C., et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195 (2002) 327-335
17. Ferlazzo G.M., Tsang L., Moretta G., Melioli G., Steiman R.M., and Munz C. Human dendritic cells activate resting NK cells and are recognized by the NKp30 receptor by activated NK cells. J Exp Med 195 (2002) 342-351
18. Piccioli D., Sbrana S., Melandri E., and Valiante N.M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195 (2002) 335-341
19. Ballas Z.D., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157 (1996) 1840-1841
20. Krieg A.M., Yi A.K., Matson S., Waldschmidt, Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
21. Vertehly D., Ishii K.J., Gursel M., Takeshita F., and Klimman D.M. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 166 (2001) 2372-2377
22. Wollmer J., Weeratna R., Payette P., Jurk M., Schetter C., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34 (2004) 251-262
23. Cho H.J., Hayashi, Dattta S.K., et al. IFN-type 1 promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by stimulatory DNA-based vaccines. J Immunol 168 (2002) 4907-4913
24. Ayash-Rashkovsky M., Weisman Z., Diveley J., Moss R.B., et al. Generation of TH1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory oligonucleotides-relevance to AIDS vaccines in developing countries. Vaccine 20 (2002) 2684-2692
25. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., et al. Prime-boost vaccination with HIV-1 gag protein and CpG oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune response. J Immunol 171 (2003) 2538-2547
26. Verthely D., Gursel M., Kenney R.T., Lifson J.D., et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from leishmania infection. J Immunol 170 (2003) 4717-4723
27. Lore K., Betts M.R., Brenchley J.M., Kuruppu J., et al. Toll like receptors ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 171 (2003) 4320-4328
28. Saez R., Echaniz P., de Juan M.D., Iribarren J.A., and Cuadrado E. HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxinucleotide. AIDS 19 (2005) 1924-1925
29. Tarazona R., Casado J.G., de la Rosa O., Torre-Cisneros J., Villanueva J.L., Sanchez B., et al. Selective depletion of CD56 dim NK cell subsets and maintenance of CD56bright NK cells in treatment-naive HIV-1 seropositive individuals. J Clin Immunol 22 (2002) 176-183
30. Trincheri G. IL-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
31. Gerosa F., Gobbi A., Zorzi P., Burg S., Briere F., Carra G., et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174 (2005) 727-734
32. Vitale M., DellaChiesa M., Charlemagne S., et al. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 106 (2005) 566-571
33. Jinushi M., Takehara T., Kanto T., Tatsumi T., Groh V., et al. Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation. Impairment in chronic hepatitis C virus infection. J Immunol 170 (2003) 1249-1256
34. Pan P.-Y., Gu P., Li Q., Xu D., Weber K., and Chen S.H. Regulation of dendritic cell function by NK cells: mechanism underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol 172 (2004) 4779-4789
35. Raulet D.H. Interplay of neural killer cells and their receptors with the adaptive immune response. Nat Immunol 5 (2004) 996-1002
36. Kamath A.T., Sheasby C.E., and Tough D.F. Dendritic cells and NK cells stimulate bystander T cells activation in response to TLR agonists trough secretion of IFN-αβ and IFN-γ. J Immunol 174 (2005) 767-776
37. Sun S., Zhang X., Tough D.F., and Sprent J. Type 1 interferon-mediated stimulation of T cells by CpG-DNA. J Exp Med 188 (1988) 2335-2342
38. Jamieson A.M., Diefenbach A., McMahon C.W., Xion N., Carlyle J.R., and Raulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17 (2002) 19-29
39. Moser J.M., Gibbs J., Jensen P.E., and Lukacher A.E. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nat Immunol 2 (2002) 189-195
40. Sivori S., Falco M., Della Chiesa M., Carlomagno S., Vitale M., Moretta L., et al. CpG and double stranded RNA trigger human NK cells by toll like receptors: induction for cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101 (2004) 10116-10121
41. Nguyen K.B., Salazar-Mather T.P., Dalod M.Y., et al. Coordinated and distinct roles for IFN-α/β, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169 (2002) 4279-4287
42. Anthony D.D., Yonkers N.L., Post A.B., Asaad R., Heinzel F.P., et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 172 (2004) 4907-4916
43. Mavilio D., Lombardo G., Benjamin J., Klim D., Follman D., Marcenaro F., et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 102 (2005) 2886-2891
44. Alter G., Malenfant J.M., Delabre R.M., Burgett N.C., Yu X.G., Lichterfeld M., et al. Increased natural killer cell activity in viremic HIV-1 infection. J Immunol 173 (2004) 5305-5311
45. Azzoni L., Papasavvas E., Cheimi J., Kostman J.R., Mounzer K., Onderein J.E., et al. Sustained impairment of IFNγ secretion in suppressed HIV-infected patients despite mature NK recovery: evidence for a defective reconstitution of innate immunity. J Immunol 168 (2002) 5764-5770
46. Mendila M., Heiken H., Becker S., Stoll M., Kemper A., Jacobs R., et al. Immunologic and virologic studies in long-term nonprogressors with HIV-1 infection. Eur J Med Res 4 (1999) 417-424
47. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 (2002) 429-433
48. Meyaard L., Hovenkamp E., Pakker N., van der Pow Kran T.C., and Miedema F. Interleukine-12 (IL-12) production in whole blood cultures from HIV-infected individuals studied in relation to IL-10 and prostaglandin E2 production. Blood 89 (1997) 570-576
49. Sivori S., Carlomagno S., Moretta L., and Moretta A. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 36 (2006) 961-967